Dr David Chang is a Radiation Oncologist at the Peter MacCallum Cancer Centre, specialising in Gynaecological and Genitourinary Oncology, where he currently serves as the Urology Radiation Oncology Tumour Stream Lead. In addition to his clinical leadership, he acts as a Clinical Lecturer within the Sir Peter MacCallum Department of Oncology at the University of Melbourne. David completed his Bachelor of Medicine and Bachelor of Surgery with Honours at the University of Western Australia in 2008 and undertook his postgraduate training in Radiation Oncology at the Peter MacCallum Cancer Centre, where he was elected and served as Chief Registrar in 2014. He attained his Fellowship of the Royal Australian and New Zealand College of Radiologists (FRANZCR) in 2016. In 2020, he was awarded a PhD in Nanomedicine from the University of New South Wales for his research on nanoparticles for cancer targeting. This work was completed under the supervision of Professor Maria Kavallaris at the Children's Cancer Institute (CCIA) while he was a Radiation Oncology Fellow at the Prince of Wales Hospital in Sydney. Prior to returning to the Peter MacCallum Cancer Centre in 2020, David served as the Director of Training at the Austin Health Radiation Oncology Department.

As a clinician-researcher with over 30 peer-reviewed publications, he is a pioneer in implementing novel radiotherapy techniques in Australia. He is one of the first Australian radiation oncologists involved in Stereotactic Arrhythmia Radioablation (STAR) for refractory ventricular tachycardia, with initial outcomes published in Heart Rhythm in 2025. Furthermore, as an investigator funded by the Victorian Cancer Agency, he was involved, alongside Chief Investigator, Associate Professor Sarat Chander, in the development of Partially Ablative Body Radiotherapy (PABR), a novel approach for the palliative treatment of bulky, unresectable sarcomas and tumours. He is also actively researching PSMA-guided metastasis-directed therapy for renal cell carcinoma and prostate cancer.

In 2025, Dr Chang secured competitive grant funding as Chief Investigator (CI) for two feasibility trials that prioritise consumer engagement. This includes an ANZGOG New Investigator Grant to evaluate Stereotactic Ablative Body Radiotherapy (SABR) for polymetastases arising from gynaecological primary cancers, and a Peter MacCallum Cancer Centre Foundation Grant (Consumer Choice) to lead the "Best of Both" (BOB) Trial, investigating a hybrid technique of High Dose Rate (HDR) Brachytherapy and SABR (utilising a rectal spacer) for low and intermediate-risk prostate cancer. Additionally, he will serve as an Associate Investigator for the MRFF-funded HIGH FIVE trial and contributes to the Quality Assurance team for the ADELE trial in endometrial cancer.

Dr Chang holds significant roles within the oncology community, serving as a member of the ANZGOG ASM Steering Committee (2022–2025) and Ovarian Tumour Working Group, as well as an Executive Committee Member of the Australasian Brachytherapy Group (2022–2025). Within his institution, he contributes to the Peter MacCallum Cancer Centre Ethics Committee and is involved in the management of the radiation oncology related webpages. A dedicated educator, he has supervised over 20 fellows and registrars, supervises medical student research projects, and provides annual lectures for VICTRANET.

Dr Chang’s contributions to medicine and research have been recognised through numerous awards, including the 2025 Peter MacCallum Cancer Centre Foundation Grant, the 2025 ANZGOG New Investigator Grant, the 2019 David Wigg Prize for Radiobiology Research (RANZCR), and the 2019 Australian Centre for Nanomedicine Travel Award. Earlier in his career, he received the FRO Bourne and Langlands Prize (2016), the Genitourinary Fellowship Grant (2016), a Children’s Cancer Institute Scholarship (2016), an Australian Postgraduate Award (2015), the CE Eddy Prize (2012), and the University of Western Australia Graduates Association Prize in Medicine (2002).